Drugs / RAMATERCEPT
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00952887 | Aug 2009 → Feb 2011 | muscular atrophy | Acceleron Pharma, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00755638 | Sep 2008 → Jul 2009 | muscular atrophy | Acceleron Pharma, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01239758 | Oct 2010 → May 2011 | Duchenne muscular dystrophy | Acceleron Pharma, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT01099761 | Apr 2010 → Jun 2011 | Duchenne muscular dystrophy | Acceleron Pharma, Inc. | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RAMATERCEPT | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108674 ↗ |
| Known as | ACE-031 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00755638 ↗ |
| Action | Inhibit | “Growth/differentiation factor 8 inhibitor” CHEMBL2108674 ↗ |
| Modality | Protein / enzyme biologic | “ACE-031, a soluble form of the human activin receptor type IIB” NCT01099761 ↗ |
| Route | Subcutaneous | “single subcutaneous dose of ACE-031” NCT00755638 ↗ |
| Target | MSTN | “Growth/differentiation factor 8 inhibitor” CHEMBL2108674 ↗ |